10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2011 | |||
Consolidated Statements Of Cash Flows | |||
Period Ending Dec 31, 2011 10-K (Filed: Feb 23, 2012) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | |
| Operating activities: | |||
| Net income | $ 2,789,059 | 2,889,749 | 2,625,592 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation expense | 72,187 | 67,240 | 64,560 |
| Amortization expense | 230,045 | 198,237 | 148,384 |
| Stock-based compensation expenses | 192,378 | 200,041 | 180,684 |
| In-process research and development impairment | 26,630 | 136,000 | 0 |
| Excess tax benefits from stock-based compensation | (40,848) | (81,620) | (80,186) |
| Tax benefits from employee stock plans | 37,231 | 82,086 | 88,368 |
| Deferred income taxes | 64,061 | 12,152 | (42,013) |
| Other non-cash transactions | 47,931 | 10,408 | 64,456 |
| Changes in operating assets and liabilities: | |||
| Accounts receivable, net | (375,736) | (348,875) | (356,462) |
| Inventories | (200,793) | (161,190) | (75,266) |
| Prepaid expenses and other assets | (13,959) | (70,466) | (65,667) |
| Accounts payable | 428,944 | (4,453) | 203,641 |
| Income taxes payable | 110,771 | (185,733) | 166,334 |
| Accrued liabilities | 300,593 | 120,065 | 109,026 |
| Deferred revenues | (29,484) | (29,728) | 48,603 |
| Net cash provided by operating activities | 3,639,010 | 2,833,913 | 3,080,054 |
| Investing activities: | |||
| Purchases of marketable securities | (5,127,790) | (5,502,687) | (2,614,046) |
| Proceeds from sales of marketable securities | 8,649,752 | 3,033,893 | 1,440,509 |
| Proceeds from maturities of marketable securities | 788,395 | 683,927 | 435,510 |
| Acquisitions, net of cash acquired | (588,608) | (91,000) | (1,247,816) |
| Capital expenditures and other | (131,904) | (61,884) | (230,057) |
| Net cash provided by (used in) investing activities | 3,589,845 | (1,937,751) | (2,215,900) |
| Financing activities: | |||
| Proceeds from issuances of senior notes, net of issuance costs | 4,660,702 | 0 | 0 |
| Proceeds from issuances of convertible notes, net of issuance costs | 0 | 2,462,500 | 0 |
| Proceeds from sale of warrants | 0 | 155,425 | 0 |
| Purchases of convertible note hedges | 0 | 362,622 | 0 |
| Proceeds from credit facility | 0 | 500,000 | 400,000 |
| Repayments of credit facility | 0 | (500,000) | (400,000) |
| Proceeds from issuances of common stock | 211,737 | 221,223 | 222,728 |
| Repurchases of common stock | (2,383,132) | (4,022,593) | (998,495) |
| Extinguishment of long-term debt | (649,987) | 0 | (305,455) |
| Repayments of long-term obligations | (1,562) | (5,786) | (5,648) |
| Excess tax benefits from stock-based compensation | 40,848 | 81,620 | 80,186 |
| Contributions from (distributions to) noncontrolling interest | (115,037) | 131,523 | (44,754) |
| Net cash provided by (used in) financing activities | 1,763,569 | (1,338,710) | (1,051,438) |
| Effect of exchange rate changes on cash | (16,526) | 77,469 | 940 |
| Net change in cash and cash equivalents | 8,975,898 | (365,079) | (186,344) |
| Cash and cash equivalents at beginning of period | 907,879 | 1,272,958 | |
| Cash and cash equivalents at end of period | 9,883,777 | 907,879 | 1,272,958 |
| Supplemental disclosure of cash flow information: | |||
| Interest paid | 62,180 | 15,748 | 8,990 |
| Income taxes paid | 621,025 | 1,129,577 | 746,224 |
| External Links | |
| GILEAD SCIENCES, INC. (GILD) Fiscal Year 2011 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |